eIF6 in human disease: From ribosome biology to clinical biomarker and therapeutic target
New Cell · 30.06.2026
DOI: 10.67176/nclq7972 ↗Kurz gefasst
Fachartikel in der Zeitschrift New Cell, online erschienen am 30.06.2026. Verfasst von Guang-Bo Yuan und 2 weiteren Autor:innen. Die Arbeit nennt 55 Literaturangaben.
Abstract (Originalsprache)
Eukaryotic initiation factor 6 (eIF6), a key regulatory molecule for ribosomal 60S subunit maturation and translation initiation, possesses a BRCT-like domain and ribosomal binding sites, enabling interactions with proteins such as RACK1, Myc, and p53. eIF6 primarily exerts its effects through multiple signaling pathways including PI3K/AKT/mTOR, Wnt/β-catenin, and epithelial-mesenchymal transformation (EMT). Consequently, its expression is elevated in various malignancies such as hepatocellular carcinoma, gastric cancer, colorectal cancer, breast cancer, and glioma. Furthermore, eIF6 serves as a key regulator of the osteogenic-osteoclastic balance in bone tissue, playing a crucial role in the progression of osteoporosis. Its abnormal expression fluctuations are also associated with various pathological states such as cardiovascular disease and fibrosis, involving physiological mechanisms spanning ribosomal biosynthesis, translational regulation, and non-canonical biological functions. This review focuses on the multifaceted functions of eIF6 and its role in disease. It summarizes mechanistic studies on eIF6 in ribosomal biogenesis, translational regulation, and non-canonical pathways, and evaluates current research progress in various diseases including Shwachman-diamond syndrome, tumors, bone metabolism abnormalities, and fibrotic diseases. The aim is to provide theoretical support for translational research on eIF6 as a potential diagnostic biomarker and therapeutic target. Future research may develop eIF6 into a multi-system disease diagnostic marker and prognostic assessment tool, while elucidating its molecular mechanisms through small-molecule inhibitors or RNA interference technologies.
Zitieren
APA
Yuan, G., Gan, W., & Xu, G. (2026). eIF6 in human disease: From ribosome biology to clinical biomarker and therapeutic target. New Cell. https://doi.org/10.67176/nclq7972
Vancouver
Yuan G, Gan W, Xu G. eIF6 in human disease: From ribosome biology to clinical biomarker and therapeutic target. New Cell. 2026. doi:10.67176/nclq7972
BibTeX
@article{Yuan2026,
author = {Yuan, Guang-Bo and Gan, Wen-Jian and Xu, Guang-Chao},
title = {eIF6 in human disease: From ribosome biology to clinical biomarker and therapeutic target},
journal = {New Cell},
year = {2026},
doi = {10.67176/nclq7972}
}
EUVIMED